Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 12/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.51 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14263119 | 0.92 | RAB9A (0.54) | NPC1RAB9ASMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL4982704 | 0.87 | CARM1 (0.55) | EPHX2EPHX1MCHR1SSTR1SSTR4 | |
| SCHEMBL4980231 | 0.85 | RAB9A (0.74) | NPC1RAB9ASMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL4979582 | 0.84 | SLC6A5 (0.59) | RAB9ASMN1; SMN2EPHX2EPHX1MCHR1 | |
| SCHEMBL4982545 | 0.83 | MCHR1 (0.66) | NPC1RAB9ASMN1; SMN2EPHX1HRH3 | |
| SCHEMBL4975779 | 0.82 | DRD4 (0.59) | NPC1RAB9ASMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL15335336 | 0.82 | EPHX2 (0.78) | EPHX2EPHX1 | |
| SCHEMBL4978994 | 0.81 | SMN1; SMN2 (0.72) | NPC1RAB9ASMN1; SMN2EPHX1HRH3 | |
| SCHEMBL3653016 | 0.81 | HTR2A (0.62) | NPC1RAB9ASMN1; SMN2EPHX1HTR2C | |
| SCHEMBL4981939 | 0.80 | EPHX1 (0.71) | NPC1RAB9ASMN1; SMN2EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | NPC1 4132/4885RAB9A 1386/4885SMN1; SMN2 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.